A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Description

The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is. Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time. Participants will be asked to * Visit the clinic for pretreatment and drug administration * Visit the clinic for checkups and tests: 1. Screening through Week 52: intially weekly, bi-weekly, later monthly 2. Week 53 through Week 260 (Year 5): 8 visits throughout the period

Conditions

Osteoarthritis (OA) of the Knee

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is. Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time. Participants will be asked to * Visit the clinic for pretreatment and drug administration * Visit the clinic for checkups and tests: 1. Screening through Week 52: intially weekly, bi-weekly, later monthly 2. Week 53 through Week 260 (Year 5): 8 visits throughout the period

A Phase 2, Two-Part, Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Tolerability of Enekinragene Inzadenovec (PCRX-201) in Subjects With Painful Osteoarthritis of the Knee

A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee

Condition
Osteoarthritis (OA) of the Knee
Intervention / Treatment

-

Contacts and Locations

Birmingham

Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States, 35235

Beverly Hills

Osteoporosis Medical Center, Beverly Hills, California, United States, 90211

Huntington Beach

Beach Physicians Medical Group Inc., Huntington Beach, California, United States, 92647

La Mesa

Horizon Clinical Research, La Mesa, California, United States, 91942

West Hills

Alliance Clinical West Hills (Focus Clinical Research), West Hills, California, United States, 91307

Daytona Beach

Arrow Clinical Trials, Daytona Beach, Florida, United States, 32117

Oldsmar

Journey Research Inc., Oldsmar, Florida, United States, 34677-4681

West Palm Beach

Palm Beach Research Center, West Palm Beach, Florida, United States, 33409

Winter Park

Conquest Research, Winter Park, Florida, United States, 32789

Lincoln

Physicians Research Collaboration, Lincoln, Nebraska, United States, 68516

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects must be willing and able to comply with the study procedures and visit schedule and able to follow verbal and written instructions.
  • * Subjects must be male or female and 45 to 80 years old, inclusive, at Screening.
  • * Subjects must exhibit symptoms associated with osteoarthritis of the index knee for ≥12 months before Screening (subject self-reporting is acceptable).
  • * Subjects must have index knee pain for \>15 days over the last month before Screening (subject self-reporting is acceptable).
  • * Subjects must have failed 2 or more therapies: Restricted physical activity as per Osteoarthritis Research Society International (OARSI) core level recommendation, ie, "structured land-based exercise" (this may include physical therapy), and failure of an additional type of conservative therapy for OA of the index knee, eg, nonselective NSAIDs or COX-2 inhibitors, in the past 12 months.
  • * Subjects must have a body mass index (BMI) ≤40 kg/m2 at Screening.
  • * Subjects must have an index knee examination indicating the index knee and the intended injection site area are free of any signs of local or joint infection at Baseline.
  • * Subjects must have an index knee Average Daily Knee Pain (NRS) between ≥5.0 and ≤9.0 at Screening and Baseline.
  • * Sexually active subjects of child-bearing potential (SOCBP) and their partners must agree to use effective birth control while in the study
  • * Subjects must have active synovitis in the index knee as determined by ultrasound Doppler.
  • * Subjects must exhibit American College of Rheumatology Criteria (clinical and radiological) for osteoarthritis as follows:
  • 1. Knee pain
  • 2. At least 1 of the following:
  • * Subjects must have K-L Grade 2, 3, or 4 in the index knee based on X-rays performed during Screening and confirmed by trained radiographers at a central facility before enrollment
  • * Subjects need to show the presence of moderate or severe synovitis based on 11-point synovitis score using contrast-enhanced MRI
  • * Subjects have any current or prior diagnosis of autoimmune connective tissue disorders, secondary OA conditions, benign synovial tumors, gout/pseudogout, reactive arthritis, RA, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease.
  • * Subjects have any active systemic or local infection, including infection of the index knee
  • * Subjects are unable to undergo MRI with contrast MRI
  • * Subjects with X-ray or MRI exclusionary events
  • * Subjects have an unstable index knee joint (eg, torn anterior cruciate ligament) within 12 months of Screening
  • * Subjects have used any approved or investigational IA drug/biologic in index knee within 6 months of Screening (eg, hyaluronic acid, platelet rich plasma, stem cells, prolotherapy, and amniotic fluid injection)
  • * Subjects are receiving or have received any gene therapy treatment (eg, IL-1Ra) in the past 3 years
  • * Subjects have used IA steroids ≤3 months before screening

Ages Eligible for Study

45 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Pacira Pharmaceuticals, Inc,

Nino Joy, MD, STUDY_DIRECTOR, Pacira Pharmaceuticals, Inc

Study Record Dates

2032-03